OptimizeRx Framtida tillväxt
Future kriterier kontrolleras 3/6
OptimizeRx förväntas öka vinsten och intäkterna med 24.3% och 1.1% per år respektive medan EPS förväntas växa med 13.6% per år.
Viktig information
24.3%
Tillväxttakt i vinsten
13.61%
Tillväxttakt för EPS
| Healthcare Services vinsttillväxt | 21.7% |
| Intäkternas tillväxttakt | 1.1% |
| Framtida avkastning på eget kapital | n/a |
| Bevakning av analytiker | Good |
| Senast uppdaterad | 13 May 2026 |
Senaste uppdateringarna om framtida tillväxt
Recent updates
Uppdatering av berättelse • May 15
OPRX: Share Repurchases And Profit Focus Will Support Future Upside Potential
The analyst fair value estimate for OptimizeRx has been reduced from $20.00 to $18.00 per share, as analysts factor in recent price target cuts tied to softer revenue guidance, client disruption, and pressure on contract durations. These factors are partly balanced by stable profit forecasts and ongoing subscription momentum.Analysartikel • May 15
Need To Know: Analysts Just Made A Substantial Cut To Their OptimizeRx Corporation (NASDAQ:OPRX) Estimates
The analysts covering OptimizeRx Corporation ( NASDAQ:OPRX ) delivered a dose of negativity to shareholders today, by...Uppdatering av berättelse • May 01
OPRX: Share Repurchases And Margin Gains Will Support Future Upside Potential
The analyst price target for OptimizeRx has moved from $32 to $20 as analysts factor in softer 2026 revenue expectations, lower revenue growth assumptions, falling peer multiples, and a higher discount rate, partly offset by improved profit margin forecasts and support from the new $10m share repurchase authorization. Analyst Commentary Recent research updates show that while price targets on OptimizeRx have been reset lower, several bullish analysts still highlight positive angles around execution, profitability, and capital allocation.
Uppdatering av berättelse • Apr 17
OPRX: Profit Execution And US$10m Buybacks Will Support Future Upside
Analysts have trimmed the blended price target for OptimizeRx to $14.50, reflecting softer 2026 revenue expectations, reduced revenue visibility, and lower peer multiples, partially offset by improved profit forecasts and support from the new $10m share repurchase authorization. Analyst Commentary Street research on OptimizeRx has turned more cautious on the revenue outlook through 2026, but there is still a split between what bullish analysts focus on and what more bearish analysts are worried about.Uppdatering av berättelse • Apr 02
OPRX: Profit Focus And Buybacks Will Support Future Share Upside
Analysts have lowered their average price targets for OptimizeRx into the low to mid teens in dollar terms, citing reduced 2026 revenue visibility, softer pharma marketing budgets, pressure from peer multiples, and a greater focus on profitability and share repurchases. Analyst Commentary Street research on OptimizeRx has converged around lower price targets but with different degrees of optimism on execution, growth prospects, and valuation.Uppdatering av berättelse • Mar 19
OPRX: Margin Discipline And Buybacks Will Support Future Upside Potential
Analysts have reduced the fair value estimate for OptimizeRx from $24.33 to $14.50, citing lower revenue growth expectations, reduced revenue visibility into 2026, and lower peer P/E multiples. These factors are partly offset by firmer profit margin forecasts and buy ratings that remain in place across several firms.Uppdatering av berättelse • Mar 05
OPRX: Expanded Point Of Care Network Will Support Further Upside
Analysts have fine tuned their OptimizeRx price target to $24.33. This reflects updated assumptions around the discount rate, long term revenue growth, profit margin and future P/E multiple.
Uppdatering av berättelse • Feb 19
OPRX: New Data Partnerships Will Support Long Term Earnings Power
Analysts now maintain their price target for OptimizeRx at $17.00, reflecting updated assumptions for discount rate, revenue growth, profit margin, and future P/E that they view as broadly offsetting each other. What's in the News Announced a data collaboration with Experian at CES 2026 to connect OptimizeRx Micro-Neighborhood audiences with Experian's identity graph for onboarding, curation, and measurement of consumer audiences at scale (Client Announcements).Uppdatering av berättelse • Feb 05
OPRX: Q3 Outperformance And 2026 Guidance Will Strengthen Long Term Earnings Power
Analysts have lifted their average price targets on OptimizeRx into a US$21 to US$32 range, citing stronger than guided Q3 performance, improved visibility after 2024, and expectations for ongoing double digit growth with expanding margins. Analyst Commentary Street research after the Q3 report has centered on stronger than guided results and higher price targets, with analysts highlighting improved earnings and better visibility beyond 2024.Uppdatering av berättelse • Jan 21
OPRX: Q3 Execution Rebound And 2026 Guidance Will Support Further Upside
Analysts have lifted their blended price targets on OptimizeRx to a range of US$21 to US$32, citing stronger than guided Q3 revenue and EPS, improved visibility after 2024 execution issues, and continuing momentum that supports expectations for double digit growth with expanding margins. Analyst Commentary Across the Street, bullish analysts are taking Q3 as a sign that OptimizeRx may be getting back on track after earlier execution issues, and they have shifted their valuation ranges higher as a result.Uppdatering av berättelse • Jan 07
OPRX: Higher Guidance And Margin Expansion Will Reshape Long Term Earnings Power
Analysts have lifted their fair value estimate for OptimizeRx from US$11.00 to US$17.00, reflecting higher price targets supported by recent revenue and EPS outperformance, improved growth visibility, and expectations for margin expansion. Analyst Commentary Street research on OptimizeRx has been broadly positive around the latest quarter, with several firms raising their price targets after revenue and EPS outperformance and clearer guidance.Uppdatering av berättelse • Dec 24
OPRX Will Extend Double Digit Revenue Trajectory With New Multi Year Partnerships
Analysts have lifted their price target on OptimizeRx by $5 to $32 per share, citing consistently strong quarterly outperformance, improving visibility after last year's weak execution, and a more durable outlook for double digit revenue growth and expanding margins. Analyst Commentary Bullish analysts are increasingly aligned around a constructive view of OptimizeRx, pointing to a series of price target hikes following its latest quarterly results.Uppdatering av berättelse • Dec 09
OPRX: Recurring Revenue Shift And 2026 Guidance Will Drive Future Upside
Analysts have nudged their price targets on OptimizeRx higher, with recent increases across the Street ranging from about $1 to $10 per share to reflect stronger than expected Q3 revenue and EPS, improved visibility, and confidence in sustained double digit growth and margin expansion. Analyst Commentary Bullish analysts highlighted that the latest quarter materially exceeded revenue expectations, driving meaningful EPS upside and reinforcing confidence in a durable, double digit growth profile.Uppdatering av berättelse • Nov 25
OPRX: Multi-Year Guidance and Recurring Revenue Will Drive Upside Momentum
OptimizeRx's analyst price target has increased from $22 to approximately $24.33 per share. This reflects ongoing revenue outperformance and improved visibility that analysts attribute to strong quarterly results and the company's growing momentum.Analysartikel • Nov 23
OptimizeRx Corporation's (NASDAQ:OPRX) 33% Share Price Plunge Could Signal Some Risk
OptimizeRx Corporation ( NASDAQ:OPRX ) shareholders won't be pleased to see that the share price has had a very rough...Uppdatering av berättelse • Nov 08
OPRX: Expanding Margins and Subscription Model Will Drive Shareholder Value Forward
OptimizeRx's analyst fair value target has been raised from $19 to $22.00 per share. This change reflects stronger quarterly results, improved growth prospects, and expanding profit margins, according to analysts.Analysartikel • Oct 07
Is OptimizeRx (NASDAQ:OPRX) Using Too Much Debt?
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysartikel • Aug 27
Are Investors Undervaluing OptimizeRx Corporation (NASDAQ:OPRX) By 39%?
Key Insights OptimizeRx's estimated fair value is US$28.97 based on 2 Stage Free Cash Flow to Equity OptimizeRx's...Uppdatering av berättelse • Aug 15
Pharmaceutical Digital Engagement Will Unlock Future Value
Despite near-term cautious revenue guidance, analysts remain optimistic on OptimizeRx due to Q2 earnings outperformance, improved management transparency, and ongoing strategic initiatives, maintaining the consensus price target at $19.00. Analyst Commentary Bullish analysts highlight OptimizeRx’s Q2 revenues and adjusted EBITDA significantly surpassing forecasts.Analysartikel • May 09
Even With A 33% Surge, Cautious Investors Are Not Rewarding OptimizeRx Corporation's (NASDAQ:OPRX) Performance Completely
OptimizeRx Corporation ( NASDAQ:OPRX ) shares have continued their recent momentum with a 33% gain in the last month...
Ny berättelse • Apr 08
A Subscription Model And EHR Network Will Reshape Healthcare
Transitioning to a subscription-based model aims to enhance revenue predictability and improve net margins with recurring income.Analysartikel • Apr 06
Is OptimizeRx Corporation (NASDAQ:OPRX) Expensive For A Reason? A Look At Its Intrinsic Value
Key Insights Using the 2 Stage Free Cash Flow to Equity, OptimizeRx fair value estimate is US$6.02 Current share price...Analysartikel • Mar 08
We Think OptimizeRx (NASDAQ:OPRX) Has A Fair Chunk Of Debt
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analysartikel • Feb 14
At US$6.29, Is It Time To Put OptimizeRx Corporation (NASDAQ:OPRX) On Your Watch List?
OptimizeRx Corporation ( NASDAQ:OPRX ), is not the largest company out there, but it received a lot of attention from a...Analysartikel • Dec 15
Market Might Still Lack Some Conviction On OptimizeRx Corporation (NASDAQ:OPRX) Even After 30% Share Price Boost
OptimizeRx Corporation ( NASDAQ:OPRX ) shareholders are no doubt pleased to see that the share price has bounced 30% in...Analysartikel • Nov 16
Does OptimizeRx (NASDAQ:OPRX) Have A Healthy Balance Sheet?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysartikel • Jul 30
OptimizeRx (NASDAQ:OPRX) Is Carrying A Fair Bit Of Debt
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Analysartikel • Jan 09
OptimizeRx Corporation's (NASDAQ:OPRX) 36% Jump Shows Its Popularity With Investors
OptimizeRx Corporation ( NASDAQ:OPRX ) shares have continued their recent momentum with a 36% gain in the last month...Prognoser för vinst- och omsättningstillväxt
| Datum | Intäkter | Intäkter | Fritt kassaflöde | Kassaflöde från rörelsen | Genomsnittligt Antal analytiker |
|---|---|---|---|---|---|
| 12/31/2027 | 108 | 10 | N/A | N/A | 7 |
| 12/31/2026 | 97 | 5 | N/A | N/A | 7 |
| 3/31/2026 | 107 | 7 | 15 | 14 | N/A |
| 12/31/2025 | 109 | 5 | 19 | 19 | N/A |
| 9/30/2025 | 110 | 0 | 12 | 12 | N/A |
| 6/30/2025 | 105 | -10 | 10 | 10 | N/A |
| 3/31/2025 | 94 | -15 | 6 | 7 | N/A |
| 12/31/2024 | 92 | -20 | 4 | 5 | N/A |
| 9/30/2024 | 88 | -24 | -1 | -2 | N/A |
| 6/30/2024 | 83 | -18 | -2 | -2 | N/A |
| 3/31/2024 | 78 | -18 | -6 | -5 | N/A |
| 12/31/2023 | 72 | -18 | -8 | -7 | N/A |
| 9/30/2023 | 63 | -14 | 0 | 2 | N/A |
| 6/30/2023 | 62 | -14 | 2 | 4 | N/A |
| 3/31/2023 | 62 | -14 | 6 | 6 | N/A |
| 12/31/2022 | 62 | -11 | 10 | 11 | N/A |
| 9/30/2022 | 63 | -10 | 6 | 7 | N/A |
| 6/30/2022 | 64 | -7 | 3 | 3 | N/A |
| 3/31/2022 | 64 | -3 | 3 | 3 | N/A |
| 12/31/2021 | 61 | 0 | 0 | 1 | N/A |
| 9/30/2021 | 57 | 1 | -1 | -1 | N/A |
| 6/30/2021 | 52 | 1 | -1 | -1 | N/A |
| 3/31/2021 | 47 | -1 | -1 | -1 | N/A |
| 12/31/2020 | 43 | -2 | -6 | -6 | N/A |
| 9/30/2020 | 34 | -6 | -6 | -5 | N/A |
| 6/30/2020 | 29 | -7 | -7 | -6 | N/A |
| 3/31/2020 | 27 | -5 | -8 | -6 | N/A |
| 12/31/2019 | 25 | -3 | N/A | -2 | N/A |
| 9/30/2019 | 24 | -1 | N/A | 1 | N/A |
| 6/30/2019 | 24 | 1 | N/A | 3 | N/A |
| 3/31/2019 | 22 | 0 | N/A | 2 | N/A |
| 12/31/2018 | 21 | 0 | N/A | 1 | N/A |
| 9/30/2018 | 19 | 0 | N/A | 0 | N/A |
| 6/30/2018 | 16 | -1 | N/A | -2 | N/A |
| 3/31/2018 | 14 | -1 | N/A | -2 | N/A |
| 12/31/2017 | 12 | -2 | N/A | -1 | N/A |
| 9/30/2017 | 10 | -2 | N/A | -2 | N/A |
| 6/30/2017 | 9 | -2 | N/A | -1 | N/A |
| 3/31/2017 | 8 | -2 | N/A | 0 | N/A |
| 12/31/2016 | 8 | -2 | N/A | 0 | N/A |
| 9/30/2016 | 7 | -2 | N/A | 0 | N/A |
| 6/30/2016 | 8 | -1 | N/A | 0 | N/A |
| 3/31/2016 | 7 | -1 | N/A | 0 | N/A |
| 12/31/2015 | 7 | -1 | N/A | 1 | N/A |
| 9/30/2015 | 7 | 0 | N/A | 1 | N/A |
| 6/30/2015 | 7 | 0 | N/A | 0 | N/A |
Analytiker Framtid Tillväxt Prognoser
Intäkter kontra sparande: OPRX s prognostiserade vinsttillväxt ( 24.3% per år) är över sparkvoten ( 3.5% ).
Resultat vs marknad: OPRX s intäkter ( 24.3% per år) förväntas växa snabbare än marknaden för US ( 16.8% per år).
Höga tillväxtresultat: OPRX s intäkter förväntas växa avsevärt under de kommande 3 åren.
Intäkt vs marknad: OPRX s intäkter ( 1.1% per år) förväntas växa långsammare än marknaden för US ( 11.6% per år).
Hög tillväxtintäkter: OPRX s intäkter ( 1.1% per år) förväntas växa långsammare än 20% per år.
Tillväxtprognoser för vinst per aktie
Framtida avkastning på eget kapital
Framtida ROE: Otillräcklig data för att avgöra om OPRX s avkastning på eget kapital förväntas bli hög om tre år
Upptäck tillväxtföretag
Företagsanalys och finansiella data Status
| Uppgifter | Senast uppdaterad (UTC-tid) |
|---|---|
| Analys av företag | 2026/05/20 08:24 |
| Aktiekurs vid dagens slut | 2026/05/20 00:00 |
| Intäkter | 2026/03/31 |
| Årlig intjäning | 2025/12/31 |
Datakällor
Den data som används i vår företagsanalys kommer från S&P Global Market Intelligence LLC. Följande data används i vår analysmodell för att generera denna rapport. Data är normaliserade vilket kan medföra en fördröjning från det att källan är tillgänglig.
| Paket | Uppgifter | Tidsram | Exempel US-källa |
|---|---|---|---|
| Företagets finansiella ställning | 10 år |
| |
| Analytikernas konsensusuppskattningar | +3 år |
|
|
| Marknadspriser | 30 år |
| |
| Ägarskap | 10 år |
| |
| Förvaltning | 10 år |
| |
| Viktiga utvecklingstendenser | 10 år |
|
* Exempel för amerikanska värdepapper, för icke-amerikanska värdepapper används motsvarande regelverk och källor.
Om inget annat anges är all finansiell data baserad på en årsperiod men uppdateras kvartalsvis. Detta kallas data för efterföljande tolv månader (TTM) eller senaste tolv månader (LTM). Lär dig mer om detta.
Analysmodell och snöflinga
Detaljer om analysmodellen som användes för att skapa den här rapporten finns på vår Github-sida, vi har också guider om hur du använder våra rapporter och tutorials på Youtube.
Lär dig mer om det team i världsklass som utformade och byggde analysmodellen Simply Wall St.
Industri- och sektormått
Våra bransch- och sektionsmått beräknas var sjätte timme av Simply Wall St, detaljer om vår process finns tillgängliga på Github.
Källor för analytiker
OptimizeRx Corporation bevakas av 12 analytiker. 7 av dessa analytiker lämnade de uppskattningar av intäkter eller resultat som användes som indata till vår rapport. Analytikernas inskickade estimat uppdateras löpande under dagen.
| Analytiker | Institution |
|---|---|
| Anderson Schock | B. Riley Securities, Inc. |
| Constantine Davides | Citizens JMP Securities, LLC |
| Eric Martinuzzi | Lake Street Capital Markets, LLC |